one
million
american
hiv
intens
care
unit
continu
see
frequent
patient
hiv
infect
era
highli
activ
antiretrovir
therapi
clinician
must
awar
drug
toxic
drug
interact
must
also
recogn
tradit
opportunist
infect
well
newer
syndrom
immun
reconstitut
syndrom
multicentr
castleman
diseas
primari
pleural
cell
lymphoma
unit
state
approxim
one
million
individu
infect
hiv
new
case
hiv
infect
year
wwwcdcgovhivstat
epidemiolog
profil
patient
hiv
infect
shift
countri
substanti
number
homosexu
male
infect
larg
urban
area
grow
proport
infect
patient
femal
resid
smaller
citi
rural
area
acquir
infect
heterosexu
via
intraven
drug
abus
chang
rang
frequenc
clinic
manifest
aid
reflect
issu
affect
women
african
american
intraven
drug
abus
popul
hivinfect
patient
also
get
older
patient
hiv
infect
benefit
improv
manag
live
longer
individu
without
hiv
infect
also
live
longer
sexual
activ
longer
extend
period
risk
acquir
hiv
infect
thu
substanti
number
resid
unit
state
hiv
infect
spectrum
affect
patient
chang
individu
hiv
infect
hospit
may
ultim
care
intens
care
unit
icu
wide
varieti
reason
reason
relat
clinic
issu
relat
directli
hiv
infect
opportunist
infect
health
care
profession
recogn
patient
also
becom
hospit
reason
hivuninfect
patient
admit
ie
hivunrel
issu
trauma
acut
infect
chronic
pulmonari
diseas
chronic
coronari
arteri
diseas
etc
latter
patient
need
manag
strategi
hivuninfect
patient
except
countri
health
care
profession
long
sinc
discard
flaw
notion
hivinfect
patient
manag
differ
sole
base
hiv
statu
rather
basi
clinic
condit
person
prefer
howev
special
differ
hivinfect
patient
first
receiv
antiretrovir
agent
decis
must
made
whether
continu
drug
hospit
see
whether
discontinu
second
certain
antiretrovir
drug
profound
receiv
origin
form
novemb
accept
final
form
novemb
correspond
request
reprint
address
henri
drugdrug
interact
must
consid
prescrib
agent
whose
pharmacokinet
might
substanti
affect
third
health
care
provid
need
cogniz
nosocomi
exposur
percutan
musos
fluid
might
hiv
infect
must
take
appropri
prevent
step
reduc
likelihood
occup
hiv
transmiss
articl
focus
patient
admit
icu
condit
relat
hiv
statu
sinc
introduct
potent
antiretrovir
agent
appar
clinician
frequenc
opportunist
infect
declin
patient
surviv
increas
declin
opportunist
infect
uniform
infecti
complic
decreas
incid
howev
neoplast
complic
affect
manner
although
kaposi
sarcoma
primari
central
nervou
system
cn
lymphoma
declin
dramat
incid
incid
nonprimari
cn
bcell
lymphoma
stabl
may
increas
term
lifetim
risk
patient
live
longer
addit
becom
appar
unusu
tumor
link
human
herpesviru
increas
multicentr
castleman
diseas
primari
effus
cell
lymphoma
solid
tumor
may
also
increas
bronchogen
carcinoma
melanoma
renal
cell
carcinoma
although
data
need
confirm
initi
observ
opportunist
infect
declin
caus
hospit
chang
proport
hospit
due
respiratori
diseas
still
consider
fall
proport
hospit
due
hepat
diseas
especi
sequela
hepat
c
renal
diseas
consequ
hiv
nephropathi
disord
cardiovascular
diseas
increas
among
pulmonari
complic
incid
pneumocysti
pneumonia
pcp
declin
fraction
pcp
case
requir
hospit
admiss
icu
fall
thu
face
hiv
infect
hospit
icu
chang
past
decad
although
face
hiv
epidem
chang
unit
state
western
europ
clinician
must
recogn
two
distinct
popul
patient
first
patient
access
care
full
armamentarium
hivrel
drug
patient
surviv
longer
opportunist
complic
fewer
note
patient
like
admit
icu
nonhivrel
problem
complic
hiv
drug
patient
may
eventu
lose
respons
antiretrovir
therapi
art
opportunist
infect
prophylaxi
perhap
continu
art
appear
fewer
infecti
complic
contrast
patient
popul
sizabl
number
individu
unit
state
either
unawar
hiv
statu
lack
access
care
patient
continu
appear
emerg
room
physician
offic
opportunist
infect
seen
manag
infect
recent
summar
nation
institut
healthcent
diseas
control
preventioninfecti
diseas
societi
america
guidelin
treatment
opportunist
infect
hivinfect
person
wwwaidsinfonihgov
patient
hiv
infect
present
health
care
provid
import
recogn
patient
may
may
hivrel
problem
clinician
often
assum
patient
opportunist
infect
neoplast
problem
metabol
disord
relat
hiv
infect
yet
patient
also
risk
common
process
even
patient
infect
infecti
process
may
caus
common
communityacquir
pathogen
opportunist
pathogen
tlymphocyt
count
continu
excel
indic
suscept
patient
hivrel
opportunist
infect
art
alter
relationship
tcell
count
occurr
opportunist
infect
establish
preart
era
differ
count
patient
art
art
minim
diagnost
signific
addit
nadir
tlymphocyt
count
littl
clinic
implic
suscept
opportunist
infect
key
paramet
current
tlymphocyt
count
nadir
count
past
subtl
differ
immunolog
function
base
nadir
count
dissect
laboratori
evalu
clear
differ
major
clinic
implic
viral
load
predict
occurr
opportunist
infect
detect
viral
load
correl
immun
activ
decreas
respons
specif
pathogen
thu
patient
given
tlymphocyt
count
high
viral
load
appear
enhanc
risk
aidsdefin
ill
patient
compar
tlymphocyt
count
low
viral
load
differ
difficult
measur
paramet
predict
suscept
opportunist
process
plasma
cytomegaloviru
cmv
viral
load
correl
suscept
high
cmv
viral
load
higher
risk
viral
load
limit
detect
whether
correl
due
direct
effect
cmv
immun
function
whether
marker
poor
immun
control
pathogen
gener
clear
clinic
paramet
import
prognost
patient
tcell
count
higher
cellsl
develop
oral
thrush
pcp
bacteri
pneumonia
higher
risk
develop
anoth
opportunist
infect
compar
patient
tcell
count
one
complic
observ
implic
differenti
diagnosi
subsequ
syndrom
initi
prophylaxi
hivinfect
patient
admit
icu
major
issu
whether
continu
art
stop
drug
intensivist
need
awar
sever
import
principl
first
antiretrovir
agent
avail
oral
tablet
suspens
part
zidovudin
enfuvirtid
agent
avail
parenter
form
thu
pharmacokinet
art
unpredict
sever
ill
patient
uncertain
gastrointestin
absorpt
potenti
drug
interact
second
proteas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
metabol
cytochrom
enzym
system
alter
metabol
drug
metabol
system
pharmacokinet
alter
produc
drug
toxic
serum
level
drug
augment
lack
efficaci
drug
level
reduc
art
even
day
suboptim
level
due
poor
absorpt
pharmacokinet
interact
disastr
result
ie
irrevers
drug
resist
occur
thu
situat
best
strategi
stop
art
icu
admiss
consult
experienc
pharmacokineticist
effect
drug
metabol
even
art
stop
stop
art
unlik
lead
drug
resist
tcell
count
may
fall
less
seriou
consequ
produc
drug
resist
stop
nonnucleosid
revers
transcriptas
inhibitor
complic
pharmacolog
advic
experienc
pharmacist
infecti
diseas
specialist
facilit
develop
optim
manag
strategi
induc
resist
due
longer
halflif
nonnucleosid
revers
transcriptas
inhibitor
compar
drug
third
drug
toxic
often
difficult
attribut
specif
drug
thu
art
ad
regimen
potenti
toxic
rash
liver
function
test
abnorm
elev
amylas
level
occur
difficult
know
whether
attribut
toxic
art
anoth
drug
diseas
process
thu
discontinu
art
simplifi
manag
clinic
issu
could
potenti
due
art
initi
art
patient
icu
caus
immun
reconstitut
syndrom
ir
life
threaten
difficult
distinguish
clinic
syndrom
describ
thu
yet
anoth
reason
reluct
initi
art
icu
patient
hiv
infect
well
recogn
candid
develop
pulmonari
diseas
due
wide
array
opportunist
nonopportunist
process
clinician
recogn
streptococcu
pneumonia
continu
common
caus
upper
lower
respiratori
diseas
patient
popul
patient
increas
incid
bacteri
respiratori
infect
tcell
strata
although
incid
increas
tcell
count
declin
haemophilu
influenza
encapsul
nonencapsul
type
also
common
grow
literatur
occurr
pneumonia
due
staphylococcu
aureu
especi
oxacillinresist
strain
pseudomona
aeruginosa
especi
among
patient
low
tcell
count
howev
pneumonia
h
influenza
continu
predomin
organ
clinic
present
diagnosi
therapi
bacteri
pneumonia
differ
substanti
hivinfect
patient
compar
hivuninfect
patient
bacteremia
extrapulmonari
diseas
appear
common
least
pneumonia
part
world
mycobacterium
tuberculosi
major
caus
pulmonari
extrapulmonari
diseas
patient
hiv
infect
contrast
unit
state
western
europ
tuberculosi
rel
uncommon
except
among
immigr
individu
special
exposur
resid
work
correct
facil
tuberculosi
must
consider
everi
patient
present
pulmonari
diseas
facilit
appropri
therapi
prevent
transmiss
health
care
worker
patient
visitor
recognit
manag
tuberculosi
complex
process
unlik
bacteri
diseas
mani
differ
recognit
manag
hivuninfect
patient
tuberculosi
present
mani
typic
atyp
form
pulmonari
extrapulmonari
manifest
patient
potenti
exposur
present
febril
ill
tuberculosi
alway
consider
given
major
predisposit
hivinfect
patient
develop
diseas
patient
infect
likelihood
diseas
estim
per
year
oppos
per
lifetim
hivuninfect
individu
treatment
tuberculosi
complic
drug
interact
art
agent
antitubercul
agent
rifampin
particular
complex
interact
proteas
inhibitor
nonnucleosid
revers
transcriptas
inhibitor
art
agent
antitubercul
drug
also
overlap
toxic
especi
liver
advers
event
guidelin
recommend
appropri
dose
drug
adjust
made
standard
regimen
treatment
tuberculosi
also
complic
occurr
ir
syndrom
discuss
syndrom
associ
recent
tuberculosi
clinic
sever
make
initi
art
much
complic
endeavor
region
tuberculosi
common
although
tuberculosi
occur
enhanc
frequenc
patient
hiv
infect
pauciti
case
pulmonari
diseas
due
mycobacterium
avium
complex
stand
mark
contrast
avium
complex
clearli
caus
consider
morbid
patient
popul
patient
tcell
count
cellsl
howev
diseas
almost
alway
manifest
mycobacteremia
lymphaden
enter
although
lung
may
colon
avium
ie
avium
may
readili
found
pulmonari
secret
organ
almost
never
caus
pulmonari
dysfunct
document
case
instanc
tissu
need
certain
anoth
process
caus
pulmonari
dysfunct
mycobacteria
occasion
caus
pulmonari
diseas
patient
hiv
infect
mycobacterium
kansasii
probabl
common
howev
mycobacteria
tuberculosi
occur
great
frequenc
caus
signific
lung
patholog
pneumocysti
jiroveci
abbrevi
pcp
indic
pneumocysti
pneumonia
continu
common
caus
pulmonari
diseas
unit
state
western
europ
pcp
occur
develop
countri
although
frequenc
set
uncertain
whether
pathogen
less
common
area
whether
pcp
underdiagnos
whether
patient
die
onset
pcp
due
diseas
process
unclear
pcp
occur
unit
state
predominantli
patient
receiv
either
art
antipneumocysti
prophylaxi
indic
outcom
patient
pcp
improv
past
decad
clinician
awar
entiti
tcell
count
cellsl
diagnosi
improv
widespread
avail
induc
sputum
examin
immunofluoresc
antibodi
stain
supplement
bronchoalveolar
lavag
transbronchi
lung
biopsi
stain
methenamin
silver
giemsa
clinician
need
cogniz
howev
case
pcp
occur
tcell
count
higher
cellsl
thu
patient
present
pulmonari
process
tcell
count
greater
cellsl
pcp
usual
first
diagnosi
consid
exclud
differenti
diagnosi
pcp
usual
present
subacut
ill
sever
week
chest
radiograph
typic
demonstr
bilater
symmetr
interstiti
infiltr
howev
atyp
present
uncommon
pcp
document
produc
lobar
infiltr
nodul
caviti
effus
thu
empir
diagnos
basi
clinic
present
less
desir
specif
diagnos
basi
direct
microscopi
cultur
type
antigen
nucleic
acid
detect
certain
correct
pathogen
treat
toxic
unnecessari
drug
avoid
extrapulmonari
pcp
also
occur
patient
hiv
infect
lesion
liver
spleen
probabl
common
howev
lesion
kidney
brain
eye
lymph
node
also
seen
distribut
shock
also
report
associ
pcp
therapi
choic
pcp
continu
trimethoprimsulfamethoxazol
tmpsmx
prednison
ad
patient
present
room
air
po
less
mm
hg
molecular
evid
mutat
like
confer
sulfonamid
resist
occur
grow
frequenc
among
hivinfect
patient
sulfa
compon
tmpsmx
probabl
activ
agent
compound
pcp
resist
could
becom
major
manag
problem
howev
clear
consensu
publish
trial
resist
alter
patient
outcom
although
sever
studi
suggest
effect
patient
toler
tmpsmx
fail
drug
effect
altern
intraven
pentamidin
drug
well
known
toxic
includ
renal
impair
dysglycemia
pancreat
dapsonetrimethoprim
effect
combin
avail
oral
form
dapson
crossreact
sulfamethoxazol
approxim
patient
thu
combin
offer
modest
breadth
antipcp
armamentarium
clindamycin
plu
primaquin
atovaquon
trimetrex
option
trimetrex
administ
parenter
parenter
form
atovaquon
primaquin
fungal
pneumonia
pcp
occur
patient
hiv
infect
common
geograph
area
cryptococcu
histoplasma
coccidioid
recogn
caus
focal
diffus
pulmonari
diseas
gener
focal
diseas
common
among
patient
higher
tcell
count
diffus
diseas
frequent
among
patient
tlymphocyt
count
lower
cellsl
diagnosi
therapi
pneumonia
differ
substanti
diseas
immunosuppress
patient
pneumonia
occur
patient
low
tlymphocyt
count
difficult
distinguish
clinic
pcp
reinforc
desir
establish
specif
diagnosi
patient
hiv
infect
present
pulmonari
patholog
patient
diseas
tcell
count
less
cellsl
therapi
must
usual
continu
throughout
life
unless
immun
reconstitut
art
aspergillu
report
caus
tracheobronchi
pulmonari
diseas
increas
frequenc
patient
typic
either
low
tcell
count
neutropenia
patient
latter
diagnosi
may
establish
bronchoscopist
recogn
characterist
plaquelik
lesion
bronchu
smearand
cultureposit
aspergillu
well
patient
surviv
earli
diagnosi
combin
fungal
therapi
remain
determin
interestingli
herpesvirus
common
caus
pulmonari
dysfunct
patient
hiv
cmv
often
found
respiratori
secret
patient
low
tlymphocyt
count
cmv
rare
caus
pulmonari
dysfunct
studi
shown
instanc
preval
cmv
respiratori
secret
correl
invers
tlymphocyt
count
also
shown
cmv
present
lung
biopsi
patient
pcp
patient
well
antipcp
therapi
alon
patient
inclus
thu
document
cmv
caus
pulmonari
dysfunct
patient
popul
requir
tissu
demonstr
multipl
inclus
bodi
absenc
anoth
like
pathogen
herp
simplex
viru
varicellazost
viru
describ
caus
pulmonari
diseas
patient
popul
howev
usual
set
dissemin
diseas
lesion
skin
appar
case
herp
simplex
viru
pneumonia
appear
extens
oropharynx
case
unusu
patient
popul
influenza
respiratori
syncyti
viru
adenoviru
coronaviru
caus
pulmonari
diseas
patient
popul
howev
evid
virus
caus
diseas
increas
frequenc
virul
patient
popul
thu
consid
hivassoci
opportunist
infect
art
initi
patient
hiv
infect
drugsensit
viru
immun
function
improv
viral
load
reduc
tcell
count
increas
improv
immunolog
respons
often
manifest
organ
dysfunct
respons
latent
appar
antigen
rang
mild
clinic
unimport
sever
life
threaten
ir
describ
case
seri
wellconstruct
studi
defin
immunolog
correl
factor
predict
occurr
observ
studi
publish
date
would
appear
syndrom
like
occur
patient
start
art
tcell
count
low
typic
less
cellsl
viral
load
high
typic
greater
copiesl
ir
occur
within
week
month
start
art
syndrom
occur
within
day
other
describ
may
manifest
mani
month
sever
year
immun
function
improv
qualit
soon
viral
load
fall
patient
ir
may
manifest
higher
tlymphocyt
count
time
ir
altern
patient
organ
sequest
focu
bone
like
late
manifest
ir
appear
common
area
tuberculosi
cryptococcosi
common
relationship
ir
specif
pathogen
defin
expert
report
instanc
ir
rare
occur
due
latent
tuberculosi
commonli
occur
due
latent
avium
complex
ir
commonli
occur
activ
tuberculosi
diagnos
cmv
retin
ir
occur
week
month
year
cmv
retin
stabil
drug
therapi
art
belatedli
initi
consensu
case
definit
ir
thu
literatur
includ
report
categor
clinic
manifest
differ
extrem
difficult
patient
present
new
clinic
syndrom
start
ir
determin
manifest
immunolog
reaction
need
specif
intervent
whether
process
repres
activ
opportunist
infect
need
therapi
seri
includ
patient
fungemia
mycobacteremia
exampl
ir
seri
would
includ
patient
case
activ
new
opportunist
infect
need
specif
therapi
uncertainti
leav
clinician
dilemma
aggress
diagnost
therapeut
syndrom
manag
without
therapi
syndrom
clinic
sever
treat
antiinflammatori
agent
includ
prednison
syndrom
treat
long
cours
specif
antiinfect
therapi
junctur
evid
base
recommend
optim
approach
kaposi
sarcoma
lymphoma
wellrecogn
caus
pulmonari
diseas
patient
hiv
infect
incid
kaposi
sarcoma
declin
epidem
move
heterosexu
individu
women
group
characterist
high
incid
kaposi
sarcoma
addit
art
use
associ
declin
tumor
link
infect
kaposi
sarcoma
occur
lung
present
patchi
bronchial
lesion
often
associ
pleural
effus
bloodi
thoracentesi
perform
diagnosi
often
anticip
concurr
skin
lesion
presenc
promin
lesion
tracheobronchi
tree
easili
recogn
bronchoscopi
diagnosi
easi
establish
definit
transbronchi
biopsi
bronchu
lung
parenchyma
reveal
crush
artifact
hard
distinguish
kaposi
sarcoma
cytolog
diagnost
featur
thu
either
tissu
must
obtain
open
lung
biopsi
videoassist
thoracoscopi
presumpt
diagnosi
must
made
kaposi
sarcoma
seen
tracheobronchi
tree
bronchoalveolar
lavag
reveal
like
pathogen
pulmonari
kaposi
sarcoma
respond
well
chemotherapi
use
art
opportunist
infect
prophylaxi
contribut
success
rate
manag
strategi
lymphoma
continu
caus
pulmonari
diseas
although
primari
cn
lymphoma
greatli
diminish
frequenc
patient
treat
art
primari
bcell
lymphoma
elsewher
continu
occur
patchi
pulmonari
infiltr
well
describ
biopsi
cytolog
need
establish
diagnosi
combin
chemotherapi
hivassoci
lymphoma
becom
impress
success
art
continu
opportunist
infect
prophylaxi
regimen
provid
brief
drug
holiday
patient
activ
receiv
chemotherapi
avoid
problem
drug
absorpt
drug
interact
howev
would
appear
activ
art
opportunist
infect
prophylaxi
import
element
contribut
improv
surviv
stem
cell
transplant
also
use
success
patient
live
longer
experi
larg
patient
number
increas
pulmonari
neoplast
process
recogn
clinician
awar
primari
effus
cell
lymphoma
present
pleural
pericardi
abdomin
caviti
present
effus
epsteinbarr
virusassoci
tumor
diagnos
cytolog
mani
case
clear
effect
chemotherapi
tumor
multicentr
castleman
diseas
anoth
unusu
neoplast
process
associ
hiv
infect
process
present
pulmonari
infiltr
well
fever
lethargi
adenopathi
cytopenia
diagnosi
usual
requir
combin
titer
bone
marrow
lymph
node
tissu
plu
flow
cytometri
patient
often
develop
lymphoma
andor
kaposi
sarcoma
subsequ
unclear
effect
therapi
diseas
sever
larg
databas
suggest
certain
solid
tumor
overrepres
patient
popul
bronchogen
carcinoma
well
melanoma
colon
cancer
breast
cancer
appear
occur
increas
frequenc
even
risk
factor
consid
clinician
must
recogn
patient
hiv
infect
acceler
atherosclerosi
clear
role
hiv
howev
art
could
conceiv
direct
toxic
effect
endotheli
cell
could
acceler
atherosclerosi
effect
insulin
resist
lipid
profil
howev
patient
present
pulmonari
syndrom
clinician
must
consid
ischem
heart
diseas
congest
heart
failur
differenti
diagnosi
addit
hivinfect
popul
age
ageappropri
atherosclerosi
increasingli
recogn
must
manag
set
hiv
care
sever
antiretrovir
agent
toxic
present
pulmonari
respiratori
manifest
patient
receiv
art
regimen
contain
abacavir
develop
hypersensit
syndrom
difficult
distinguish
nonspecif
febril
respiratori
ill
howev
abacavir
hypersensit
reaction
fatal
syndrom
must
recogn
patient
present
initi
wk
abacavir
therapi
fever
rash
fatigu
nausea
vomit
patient
cough
patient
describ
pulmonari
infiltr
syndrom
usual
persist
unless
drug
discontinu
featur
clinician
must
awar
danger
rechalleng
patient
syndrom
may
stop
take
drug
due
system
ill
nausea
vomit
case
distribut
shock
fatal
occur
rechalleng
thu
expert
would
recommend
potenti
syndrom
occur
drug
discontinu
rechalleng
permit
link
abacavir
hypersensit
syndrom
hla
clear
yet
whether
screen
patient
genotyp
would
costeffect
anoth
drug
toxic
present
dyspnea
occur
patient
receiv
nucleosid
antiretrovir
agent
long
period
time
nucleosid
zidovudin
stavudin
didanosin
lamivudin
abacavir
emtricitabin
probabl
caus
syndrom
although
best
describ
didanosin
stavudin
syndrom
reflect
mitochondri
toxic
patient
syndrom
often
femal
obes
hepat
steatosi
frequent
associ
diseas
patient
present
weak
fatigu
eventu
develop
lactic
acidosi
serum
lactat
level
typic
consider
mmoll
patient
may
appear
septic
although
usual
febril
effect
therapi
stop
drug
intervent
carnitin
riboflavin
document
benefit
whether
patient
subsequ
safe
rechalleng
nucleosid
well
studi
although
abacavir
lamivudin
ftc
seem
impart
littl
risk
clinic
featur
patient
hiv
infect
present
icu
chang
past
yr
patient
hiv
infect
live
longer
seen
icu
issu
unrel
hiv
infect
admit
icu
whatev
reason
intensivist
need
knowledg
complex
issu
relat
efficaci
toxic
art
new
manifest
ir
prematur
atherosclerosi
emerg
hivinfect
patient
icu
clearli
popul
requir
special
expertis
optim
manag
